首页 阿玛琳(usAMRN)-基本信息

阿玛琳(usAMRN)-基本信息

日报更新时间:04-15 10:22

周报更新时间:04-11 03:39

行情信息

今开价:5.03

最高价:5.07

成交量:4399135.0

昨收价:5.01

最低价:4.86

最新价:5.02

行情图标
概要信息

中文名称:阿玛琳


英文名称:Amarin Corp PLC


行业:医疗


简介:Amarin Corporation Plc是一家生物制药公司,专长脂质科学方面,致力于心血管健康治疗方案的商业化发展


电话:353-1-6699020


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

阿玛琳公司的领先产品包含凭医生处方才能买到的omega-3脂肪酸胶囊——Vascepa®,用于患有严重高三酸甘油脂血症的成人患者作为饮食添加剂,借以降低三酸甘油酯浓度。此外,Amarin Corporation还开发Vascepa用于治疗史他汀类药物治疗的三酸甘油酯高浓度患者,借以提高其低密度脂蛋白胆固醇浓度。阿玛琳公司Amarin Corporation(AMRN)历史百科: 2007年12月,Amarin Corporation以8100万美元收购Ester Neurosciences; 2012年7月26日,阿玛琳公司的Vascepa (AMR-101)获得FDA批准上市,是GlaxoSmithKline旗下Lovaza的主要竞争对手。 2018年9月24日,Amarin公司宣布其Vascepa心血管临床试验取得了积极成果,股价暴涨+314.7%。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-10 Stack (David M) Director Buy 28847 2.19
2019-07-10 Stack (David M) Director Sell 51991 22.28
2019-07-10 Stack (David M) Director Buy 23144 2.50
2019-07-04 Zakrzewski (Joseph S. JR) Director Sell 100000 23.82
2019-07-04 Zakrzewski (Joseph S. JR) Director Buy 100000 9.00
2019-07-02 Berg (Aaron D.) Officer Sell 29250 22.64
2019-07-02 Berg (Aaron D.) Officer Buy 29250 2.80
2019-07-01 Berg (Aaron D.) Officer Sell 50000 20.46
2019-07-01 Berg (Aaron D.) Officer Sell 19564 21.42
2019-07-01 Berg (Aaron D.) Officer Buy 69564 2.50
2019-06-30 Kennedy (Joseph T) General Counsel Buy 18764 2.50
2019-06-30 Kennedy (Joseph T) General Counsel Sell 54186 19.52
2019-06-30 Kennedy (Joseph T) General Counsel Buy 3438 2.95
2019-06-30 Kalb (Michael Wayne CPA) Chief Financial Officer Buy 50000 2.19
2019-06-30 Kalb (Michael Wayne CPA) Chief Financial Officer Sell 50000 19.67
2019-06-30 Kennedy (Joseph T) General Counsel Buy 2438 3.80
2019-06-30 Kennedy (Joseph T) General Counsel Buy 2604 1.40
2019-06-29 Kennedy (Joseph T) General Counsel Buy 6250 --
2019-06-29 Kennedy (Joseph T) General Counsel Sell 26495 19.39
2019-06-29 Kennedy (Joseph T) General Counsel Buy 47187 --
2019-06-29 Thero (John F) Chief Executive Officer Buy 37500 --
2019-06-29 Thero (John F) Chief Executive Officer Sell 14757 19.39
2019-06-23 Berg (Aaron D.) Officer Buy 100000 2.50
2019-06-23 Berg (Aaron D.) Officer Sell 113195 18.59
2019-06-17 Zakrzewski (Joseph S. JR) Director Sell 100000 19.02

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Lord, Abbett & Co LLC 2256449 0.68% 1196279 112.84% 2019-03-31
Sofinnova Ventures 5208305 1.57% -- -- 2019-03-31
Oracle Investment Management Inc 5226580 1.58% 25000 0.48% 2019-03-31
Perceptive Advisors LLC 6540957 1.98% 1665357 34.16% 2019-03-31
OppenheimerFunds Inc 7854114 2.38% -35141 -0.45% 2019-03-31
venBio Select Advisor LLC 8000000 2.42% 2425000 43.50% 2019-03-31
Invesco Ltd (OFI / OppenheimerFunds) 9153823 2.56% -4874 -0.05% 2019-07-31
Baker Bros Advisors LP 43210459 13.07% 617635 1.45% 2019-03-31
Consonance Capital Management LP 10990975 3.32% 1540212 16.30% 2019-03-31
T. Rowe Price Associates, Inc. 4852101 1.47% 1378967 39.70% 2019-03-31
Rock Springs Capital Management LP 4525000 1.37% 49000 1.09% 2019-03-31
Point72 Asset Management, L.P. 4101323 1.24% -2437596 -37.28% 2019-03-31
Adage Capital Partners Gp LLC 2475000 0.75% 500000 25.32% 2019-03-31
ClearBridge Advisors, LLC 2656312 0.80% -237170 -8.20% 2019-03-31
BlackRock Fund Advisors 3233629 0.91% 33445 1.05% 2019-07-31
Millennium Management LLC 3167437 0.96% -2456894 -43.68% 2019-03-31
Farallon Capital Management, L.L.C. 3250000 0.98% -250000 -7.14% 2019-03-31
BlackRock Inc 3376768 1.02% 27414 0.82% 2019-03-31
Susquehanna Financial Group, LLLP 3749908 1.13% 3574054 2032.40% 2019-03-31
Susquehanna International Group, LLP 3749908 1.13% 574054 18.08% 2019-03-31
ClearBridge Investments, LLC 2356799 0.71% 84380 3.71% 2019-06-30
Heights Capital Management Inc 3000000 0.91% 3000000 -- 2018-12-31
Healthcor Management LP 3046083 0.92% 3046083 -- 2018-12-31
OFI Global Asset Management, Inc. 9116418 2.76% -2919 -0.03% 2019-04-30
Parallax Volatility Advisers, LLC 2962895 0.90% 2962895 -- 2018-09-30
Morgan Stanley - Brokerage Accounts 3217275 0.99% -300213 -8.53% 2018-09-30
ClearBridge, LLC 5324156 1.63% 547710 11.47% 2018-06-30
Morgan Stanley & Co Inc 3196047 0.98% 252414 8.57% 2018-06-30
Fidelity Management & Research Company 3222372 0.99% 543698 20.30% 2018-11-30
Broadfin Capital, LLC 2078799 0.66% 928350 80.69% 2018-03-31
Fidelity Management and Research Company 5335221 1.69% 1952118 57.70% 2018-06-30
FMR Inc 5335221 1.74% 1952118 57.70% 2018-06-30
Stonepine Capital Management Llc 5670205 1.93% -91376 -1.59% 2018-06-30
Balyasny Asset Management LLC 1887833 0.64% -1226248 -39.38% 2018-06-30
Renaissance Technologies Corp 1769225 0.60% -832910 -32.01% 2018-06-30
Opaleye Management Inc 1750000 0.60% 5000 0.29% 2018-06-30
Deutsche Bank AG 1669446 0.57% -315821 -15.91% 2018-06-30
Invesco Advisers, Inc 1568347 0.53% 1568347 -- 2018-06-30
Alkeon Capital Management, LLC 1950000 0.66% 1950000 -- 2018-03-31
Highland Capital Management Fund Advisors, L.P. 1111399 0.41% 661399 146.98% 2017-12-31
Highland Capital Management LP 1197000 0.44% 723000 152.53% 2017-12-31
Two Sigma Investments LLC 1547977 0.57% 450755 41.08% 2017-12-31
Great Point Partners LLC 1056825 0.39% 1056825 -- 2017-12-31
Tekla Capital Management LLC 956300 0.35% -- -- 2017-12-31
University of Notre Dame Du Lac 803888 0.30% 803888 -- 2017-09-30
D. E. Shaw & Co LP 755108 0.28% -280517 -27.09% 2016-09-30
Franklin Advisers Inc 4649958 1.73% 4649958 -- 2016-09-30
Acadian Asset Management LLC 6264045 2.33% 6166576 6326.70% 2016-09-30
Aristeia Capital, L.L.C. 9376154 3.00% 21940200 -- 1999-11-30
Camber Capital Management LLC 12000000 3.00% 28080000 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
T. Rowe Price New Horizons Fund 447490 0.13% -1400 -0.31% 2019-06-30
Value Line Capital Appreciation Fund 970000 0.27% 170000 21.25% 2019-06-30
Federated Kaufmann Fund 1000000 0.28% -- -- 2019-03-31
Invesco Oppenheimer Intl Dvrs Fd 1082658 0.30% 7700 0.72% 2019-06-30
Lord Abbett Growth Leaders Fund 1505366 0.42% -- -- 2019-05-31
ClearBridge Small Cap Fund 2356799 0.66% 84380 3.71% 2019-06-30
iShares Nasdaq Biotechnology ETF 3233629 0.91% 33445 1.05% 2019-07-30
T. Rowe Price Health Sciences Fund 3338588 0.93% -161800 -4.62% 2019-06-30
Invesco Oppenheimer Intl Sml-Mid Com Fd 7834530 2.19% -- -- 2019-06-30
Value Line Larger Companies Focused Fund 770000 0.22% 80000 11.59% 2019-06-30
Fidelity 701531 0.20% -- -- 2019-06-30
Lord Abbett Developing Growth Fund 669952 0.19% 3732 0.56% 2019-05-31
Biotech Growth Trust Plc 467600 0.13% -- -- 2019-04-30
Goldman Sachs Small/Mid Cap Growth Fund 475781 0.13% -- -- 2019-06-30
Polar Capital Biotechnology Fund 500000 0.14% 50000 11.11% 2019-06-30
LSP Life Sciences Fund N.V. 508916 0.14% 102465 25.21% 2019-07-31
Hood River Small-Cap Growth Fund 569846 0.16% 22957 4.20% 2019-03-31
Federated Kaufmann Small Cap Fund 585000 0.16% 585000 -- 2019-03-31
C WorldWide Healthcare Select 611329 0.17% -150000 -19.70% 2019-07-31
ESPA Stock Biotec 656000 0.18% -- -- 2019-06-30
Invesco Health Care Fund 403082 0.12% -- -- 2019-03-31
HBM Healthcare Investments AG 700000 0.21% 700000 -- 2018-12-31
C WorldWide Medical 500000 0.15% -- -- 2019-04-30
Oppenheimer International Small-Md Co Fd 7834530 2.37% -- -- 2019-03-31
Oppenheimer International Div Fund 1049551 0.32% 9455 0.91% 2019-03-31
AdvisorShares New Tech and Media ETF 265102 0.08% 158860 149.53% 2019-03-29
ON ClearBridge Small Cap Portfolio 327010 0.10% -297720 -47.66% 2018-12-31
C WorldWide Medical Small & Mid Cap 261329 0.08% 128463 96.69% 2019-02-28
CS (Lux) Multi-Advisor Equity Alpha Fund 195123 0.06% 195123 -- 2018-11-30
Highland Long/Short Equity Fund 300000 0.09% 300000 -- 2018-09-30
Highland Long/Short Healthcare Fund 225000 0.07% -25000 -10.00% 2018-09-30
VALIC Company I Health Sciences Fund 233908 0.07% 4239 1.85% 2018-11-30
T. Rowe Price Health Sciences Port 231138 0.07% 231138 -- 2018-09-30
FPIL Invesco Global Health Care 324388 0.10% -68436 -17.42% 2018-09-30
Allianz Biotechnologie 269478 0.08% -71870 -21.05% 2018-09-30
ALPS Medical Breakthroughs ETF 474416 0.15% -- -- 2018-11-30
Polar Capital Healthcare Opps Fund 2514183 0.77% 1122404 80.65% 2018-10-31
Fidelity Advisor 287159 0.09% -- -- 2018-06-30
Tekla Healthcare Investors 332151 0.10% -- -- 2018-06-30
Oppenheimer International Small-Mid Co A 7834530 2.64% -- -- 2018-07-31
ClearBridge Small Cap C 4153479 1.40% 244710 6.26% 2018-07-31
iShares Nasdaq Biotechnology 3297209 1.08% -6276 -0.19% 2018-09-12
Invesco Global Health Care A 1362354 0.46% 1362354 -- 2018-06-30
Ohio National ClearBridge Small Cap 925850 0.31% 35760 4.02% 2018-06-30
Columbia Overseas Value Z 436990 0.15% -- -- 2018-07-31
Oppenheimer International Diversified A 842828 0.28% -14932 -1.74% 2018-07-31
Highland Long/Short Healthcare A 250000 0.09% -300000 -54.55% 2018-06-30
Sterling Capital Long/Short Equity A 85601 0.03% -14572 -14.55% 2017-12-31
VALIC Company I Health Sciences 154269 0.05% -- -- 2018-07-31
SPDR 151731 0.05% -- -- 2018-09-13
Tekla Life Sciences Investors 145998 0.05% -- -- 2018-06-30
Invesco VI Global Health Care II 205993 0.07% 205993 -- 2018-06-30
ProShares Ultra Nasdaq Biotechnology 112464 0.04% -5049 -4.30% 2018-06-30
Neuberger Berman Small Cap Growth Inv 100000 0.04% -- -- 2017-12-31
Columbia International Value A 177530 0.10% -- -- 2016-05-31
Oppenheimer Active Allc A 86841 0.03% 820 0.95% 2016-12-31
SEI World Equity Ex-US A (SIIT) 68974 0.03% -253839 -78.63% 2017-01-31
Wilmington Multi-Manager Alts A 65000 0.02% -- -- 2016-12-31
Oppenheimer Equity Inv A 52938 0.02% 219 0.42% 2016-12-31
Columbia Global Opportunities A 39877 0.01% -- -- 2016-12-31
Oppenheimer Moderate Inv A 27095 0.01% 211 0.78% 2016-12-31
Fidelity® Select Biotechnology Portfolio 4624866 2.50% -- -- 2015-09-30
Fidelity Advisor® Biotechnology Fund 1077203 0.60% -- -- 2015-09-30
Columbia Overseas Value Fund 627752 0.30% -194280 -23.60% 2015-09-30
Ohio National ClearBridge Small Cap Port 196210 0.10% 196210 -- 2015-09-30
Columbia International Value Fund 176318 0.10% -54108 -23.50% 2015-09-30
Columbia Global Opportunities Fund 157758 0.10% -50907 -24.40% 2015-09-30
Oppenheimer Port Ser Active Allc Fund 95638 -- 88288 1.00% 2015-09-30
SPDR® S&P International Small Cap ETF 63637 -- -- -- 2015-11-18
Hector Sicav CGP Patrimonia 60000 -- -- -- 2015-06-30
Oppenheimer Port Ser Equity Inv Fund 57915 -- 53464 1.00% 2015-09-30
Fidelity® NASDAQ Composite Index® Fund 44361 -- -- -- 2015-09-30
Oppenheimer Port Ser Moderate Inv Fund 29281 -- 27033 1.00% 2015-09-30
Oppenheimer International Small Co Fund 5296270 2.90% 4911918 1.00% 2015-09-30

Steven B. Ketchum Currently, Steven B. Ketchum holds the position of Chief Scientific Officer & Senior Vice President at Amarin Corp. Plc. Dr. Ketchum is also on the board of Sunesis Pharmaceuticals, Inc. In the past he occupied the position of Senior VP-Operations & Regulatory Affairs at IntraBiotics Pharmaceuticals, Inc., Senior VP-Medical Affairs, Research & Development at Reliant Pharmaceuticals LLC and Senior Director-Regulatory Affairs at ALZA Corp. Dr. Ketchum received an undergraduate degree from Stanford University and a doctorate from University College London.
Joseph T. Kennedy Currently, Joseph T. Kennedy is Secretary, EVP-General Counsel & Strategic at Amarin Corp. Plc and Secretary at Amarin Pharma, Inc. (a subsidiary of Amarin Corp. Plc). In the past Mr. Kennedy was VP & US Counsel Corporate Business Development at Elan Corp. Plc, Secretary, Vice President & General Counsel for Transcept Pharmaceuticals, Inc. and Chief Legal Officer & Vice President at Eyetech Pharmaceuticals, Inc. He received an undergraduate degree from Fairfield University and a graduate degree from New York Law School.
Patrick J. O'Sullivan Patrick J. O'Sullivan is on the board of Amarin Corp. Plc and Member of The Pharmaceutical Society of Ireland. In the past Mr. O'Sullivan held the position of Non-Executive Director at Merrion Pharmaceuticals Plc and Chief Executive Officer at LEO Laboratories Ltd. (Ireland). Patrick J. O'Sullivan received an undergraduate degree and an MBA from University College Dublin.
Jan G. van Heek Jan G. van Heek is on the board of Amarin Corp. Plc and Minerva Neurosciences, Inc. and Partner & Principal at Bio Point Group LLC. In his past career he was Chairman-Supervisory Board of to-BBB technologies BV, Chairman at BioVex Group, Inc., Chairman for BioVex, Inc., Executive Vice President of Genzyme Ltd, Executive Vice President for Genzyme Corp. and Principal at Baxter Healthcare Corp. Mr. Van Heek received an MBA from the University of St. Gallen and an MBA and an undergraduate degree from Stanford University.
John F. Thero John F. Thero occupies the position of President, Chief Executive Officer & Director at Amarin Corp. Plc and President, CEO, Treasurer & Director at Amarin Pharma, Inc. (a subsidiary of Amarin Corp. Plc). Mr. Thero is also on the board of Chiasma, Inc. In his past career he was Chief Financial Officer & Treasurer for ABIOMED, Inc., Chief Financial Officer at PerkinElmer, Inc. (United States) and Chief Financial Officer for ViaCell, Inc. (a subsidiary of PerkinElmer, Inc. (United States)), Chief Financial Officer, Secretary & Treasurer at Acusphere, Inc. and Chief Financial Officer at Aries Technology, Inc. John F. Thero received an undergraduate degree from College of the Holy Cross (Massachusetts).
David M. Stack Founder of hi5 Networks, Inc. and Stack Pharmaceuticals, Inc., David M. Stack is a businessperson who has been the head of 5 different companies and presently occupies the position of Chairman, Chief Executive & Operating Officer at Pacira Biosciences, Inc., Chairman for Chiasma, Inc. and President & Managing Partner at Stack Pharmaceuticals, Inc. David M. Stack is also on the board of 6 other companies. In his past career he occupied the position of President, Chief Executive Officer & Director at The Medicines Co., President & General Manager at Innovex, Inc., Managing Director at Mpm Capital LLC, Director-Business Development for Infectious Disease of Central Florida PA, Vice President-Business Development & Marketing at Immunomedics, Inc., Director at Endeavor Pharmaceuticals, Inc., Director at QRxpharma Ltd. (United States), Director-Business Development & Planning at Roche Laboratories, Inc. and Principal at PT Trans Corpora. David M. Stack received an undergraduate degree from Siena College and an undergraduate degree from Albany College of Pharmacy & Health Sciences.
Joseph S. Zakrzewski Joseph S. Zakrzewski is a businessperson who has been at the head of 6 different companies. Mr. Zakrzewski holds the position of Executive Chairman of Thrasos Therapeutics, Inc. He is also on the board of 10 other companies. Mr. Zakrzewski previously occupied the position of Non-Executive Chairman at Onxeo SA, Chairman for Promedior, Inc., Vice President-Corporate Business Development at Eli Lilly & Co., Chairman & Chief Executive Officer of Amarin Pharmaceuticals, Inc., Chairman, President & Chief Executive Officer at Xcellerex, Inc., Chief Operating Officer for Reliant Pharmaceuticals LLC and Venture Partner at OrbiMed Advisors Private Equity. Mr. Zakrzewski received an MBA from Indiana University and a graduate degree and an undergraduate degree from Drexel University.
Aaron D. Berg Aaron D. Berg occupies the position of Chief Commercial Officer & Senior Vice President at Amarin Corp. Plc. Mr. Berg is also on the board of American Heart Association, Inc. In the past Mr. Berg occupied the position of Principal at Bristol-Myers Squibb Co., Vice President-Marketing at Oscient Pharmaceuticals Corp., President, Chief Executive Officer & Director at Essentialis, Inc., Principal at Schering-Plough Corp., Principal at GlaxoSmithKline, Inc. and Vice President-Marketing & Sales at KOS Pharmaceuticals, Inc. Mr. Berg received an undergraduate degree from the University of Maryland.
Lars G. Ekman Lars G. Ekman, M.D., Ph.D., is Chairman of our Board of Directors, a position he has held since 2012. He is an executive partner at Sofinnova Ventures, Inc. (a venture capital firm), a position he has held since 2008. Dr. Ekman is also Chairman of the Board of Sophiris Bio Inc. (a biopharmaceutical company), where he also served as President from 2011 to 2012. He also is Chairman of the Board of Amarin Corporation plc, serves as a director of Spark Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., served as a director of Ocera Therapeutics, Inc. (from 2009 to 2015) and served as a director of InterMune Inc. (from 2006 to 2014). Dr. Ekman co-founded Cebix Incorporated, where he served as Chief Executive Officer from 2009 to 2012. He was President of Research & Development at Elan Corporation, plc (from 2001 to 2007), where he also served as a director (from 2005 to 2012). From 1997 to 2001, Dr. Ekman was Executive Vice President, Research & Development at Schwarz Pharma AG. Prior to that, he held various senior positions at Pharmacia Corporation. Dr. Ekman is a board-certified surgeon with a Ph.D. in experimental biology, and has held several clinical and academic positions in both the United States and Europe. He earned his Ph.D. and M.D. from the University of Gothenburg, Sweden. Dr. Ekman has served on our Board since 2012. Age: 67
Elisabeth Schwartz Currently, Elisabeth Schwartz occupies the position of Investor Relations & Communications Contact at Amarin Corp. Plc.
Kristine Peterson Kristine Peterson is on the board of ImmunoGen, Inc. and 7 other companies. Ms. Peterson previously held the position of Chief Executive Officer for Valeritas Holdings, Inc. and Chief Executive Officer & Director at Valeritas, Inc. (a subsidiary of Valeritas Holdings, Inc.), Group Chairman-Biotech Groups at Johnson & Johnson, Principal at Bristol-Myers Squibb Co., President at Biovail Pharmaceuticals LLC and Senior Vice President-Commercial Operations at Biovail Corp. Ms. Peterson received an MBA and an undergraduate degree from the University of Illinois.
Michael W. Kalb Currently, Michael W. Kalb is Chief Financial Officer & Senior Vice President at Amarin Corp. Plc and Chief Financial Officer at Taro Pharmaceuticals U.S.A., Inc. Mr. Kalb previously held the position of Director-Accounting & Financial Consulting Group at Huron Consulting Group, Inc. and Chief Financial & Accounting Officer, Group VP at Taro Pharmaceutical Industries Ltd. Mr. Kalb received an undergraduate degree from State University of New York at Albany.
Daniel Dunham Daniel Dunham is Chief Pharmaceutical Compliance Officer & SVP at Amarin Corp. Plc. In his past career he held the position of Principal at Pfizer Inc. and Principal at Pharmacia Corp. (a subsidiary of Pfizer Inc.), Principal at Astellas US LLC, Principal at Aptalis Pharma US, Inc., Vice President-Global Marketing at AstraZeneca LP, Chief Compliance Officer & Senior Vice President at Synergy Pharmaceuticals LLC and Chief Compliance Officer & Senior Vice President at Health Diagnostic Laboratory, Inc. He received a graduate degree from Columbia University.
Craig B. Granowitz Currently, Craig B. Granowitz holds the position of Chief Medical Officer at Amarin Corp. Plc. He is also on the board of American Heart Association (New York), American Associates Ben Gurion University of The Negev, Columbia University College of Physicians & Surgeons and Rabbinical College of America. He previously was Senior VP, Head-Medical Affairs & Human Health at Merck & Co., Inc. and Vice President & Head-Global Medical Affairs at Schering-Plough Corp. (a subsidiary of Merck & Co., Inc.).
Derek Kalinowski Presently, Derek Kalinowski holds the position of SVP-Manufacturing Operations at Amarin Corp. Plc. In the past he was Head-Supply Chain Division at Enzon Pharmaceuticals, Inc. and Vice President-Supply Chain at Sigma-Tau Pharmaceuticals, Inc.
Elisabeth Schwartz Currently, Elisabeth Schwartz occupies the position of Investor Relations & Communications Contact at Amarin Corp. Plc.
Donna Pasek Presently, Donna Pasek occupies the position of Vice President-Human Resources at Amarin Corp. Plc. In the past Ms. Pasek held the position of Head-Human Resources of EKR Therapeutics, Inc. and Vice president-Human Resources at Reliant Pharmaceuticals LLC.
Rebecca Juliano Rebecca Juliano occupies the position of Senior VP-Clinical Research & Development at Amarin Corp. Plc. He received an undergraduate degree from the University of California, Santa Cruz and a doctorate from Columbia University.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐